Main Article Content



Protein kinases have been broadly considered as significant class of target in cancer therapeutics. The mammalian target of rapamycin (mTOR) belongs to a group of protein kinases regulating cell growth and protein synthesis. Rapamycin, a natural antifungal antibiotic, can that inhibit protein kinases by partner with its intracellular receptor FKBP12. The FKBP12-rapamycin complex ties straight forwardly to the FKBP12-Rapamycin Binding (FRB) space of mTOR. Side effects in patients consuming rapamycin include: severe mood swings, small purple spots over the body retention, face allergy and anxiety. Based on recent literatures, it is understood that drug like molecules from drug bank were used to screen for potential inhibitors by docking into the active site of mTOR. A few studies used in silico tool like GLIDE, which yielded useful information about several docked structures. The drug like molecules which were complexed with mTOR could be subjected to molecular simulation studies with molecules like DB00094, which was previously reported as fertility agent targeting follicle stimulating hormone receptor. Recent literature studies have demonstrated progress in identifying mTOR drug targets in treating lung cancers and in this paper we have updated the docking score methods using in silico tools.

mTOR, protein kinases, lung cancer, inhibitors, docking scores

Article Details

How to Cite
Review Article


Vezina C, Kudelski A and Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721–726.

Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol. 1993;13:6012–6023.

Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73:585–596.

Vassiliki Papadimitrakopoulou. Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer. State Of The Art: Concise. 2012;7(8):1315-1326.

Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35–43.

Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369:756–758.

Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815–822.

Kim DH, Sarbassov D, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11:895–904.

Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110: 163–175.

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–189.

Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MM. Two TOR complexes, only one of which is rapamycin-sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10: 457–468.

Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302.

Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6: 1122–1128.

Liang J, Jin Z, Kuang J, Feng H, Zhao Q, Yang Z, Zhan L, Shen B, Yan J, Cai W, Cheng X, Qiu W. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021;125(3):390-401.

Lu Y, Yin W, Alam MS, Kadi AA, Jahng Y, Kwon Y, Rahman AFMM. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics. Anticancer Agents Med Chem. 2020;20(4):464-475.

Kaur H, Singh J, Narasimhan B. Indole hybridized diazenyl derivatives: synthesis, antimicrobial activity, cytotoxicity evaluation and docking studies. BMC Chem. 2019; 13(1):65.

Haque MW, Bose P, Siddique MUM, Sunita P, Lapenna A, Pattanayak SP. Taxifolin binds with LXR (α & β) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway. Biomed Pharmacother. 2018;105:27-36.

Singh P and Bast F. Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro. Med Oncol. 2015;32(9):233.

Rashid M, Husain A, Shaharyar M, Mishra R, Hussain A, Afzal O. Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents. Eur J Med Chem. 2014;83:630-45.

Ojo OA, Aruleba RT, Adekiya TA, Sibuyi NRS, Ojo AB, Ajiboye BO, Oyinloye BE, Adeola HA, Fadaka AO. Deciphering the interaction of puerarin with cancer macromolecules: An in silico investigation. J Biomol Struct Dyn. 2022;40(2):848-859.

Thirunavukkarasu MK, Suriya U, Rungrotmongkol T, Karuppasamy R. In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach. Pharmaceutics. 2021; 14(1):59.

Onder FC, Durdagi S, Kahraman N, Uslu TN, Kandemir H, Atici EB, Ozpolat B, Ay M. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies. Bioorg Chem. 2021;116:105296.

Karnik KS, Sarkate AP, Lokwani DK, Narula IS, Burra PVLS, Wakte PS. Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach. J Biomol Struct Dyn. 2021;39(15):5376-5398.

James N, Shanthi V, Ramanathan K. Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors. Appl Biochem Biotechnol. 2020;190(4):1127-1146.

Yadav SK, Yadav RK, Yadava U. Computational investigations and molecular dynamics simulations envisioned for potent antioxidant and anticancer drugs using indole-chalcone-triazole hybrids. DNA Repair (Amst). 2020;86:102765.

Yadav M, Dhagat S, Eswari JS. Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands. Curr Drug Discov Technol. 2020;17(2):183-190.

James N, Ramanathan K. Ligand-Based Pharmacophore Screening Strategy: a Pragmatic Approach for Targeting HER Proteins. Appl Biochem Biotechnol. 2018;186(1):85-108.

James N, Ramanathan K. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy. Cell Biochem Biophys. 2018;76(1-2):111-124.

James N, Shanthi V, Ramanathan K. Drug Design for ALK-Positive NSCLC: An Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy. Appl Biochem Biotechnol. 2018;185(1):289-315.

Li DD, Meng XF, Wang Q, Yu P, Zhao LG, Zhang ZP, Wang ZZ, Xiao W. Consensus scoring model for the molecular docking study of mTOR kinase inhibitor. J Mol Graph Model. 2018;79:81-87.

Singh P, Bast F. Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro. Med Oncol. 2015;32(9):233.

Aziz MW, Kamal AM, Mohamed KO, Elgendy AA. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Bioorg Med Chem Lett. 2021;41:127987.

Matada GSP, Abbas N, Dhiwar PS, Basu R, Devasahayam G.. Design, Synthesis, In Silico and In Vitro Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors. Anticancer Agents Med Chem. 2021;21(4):451-461.

Alam N, Najnin H, Islam M, Iqbal S, Zaidi R. Development of a Lung Cancer Model in Wistar Rat and in silico Screening of its Biomarkers. Curr Comput Aided Drug Des. 2021;17(3):458-468.

Ji L, Wu M, Li Z. Utacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway. Molecules. 2018;23(8): 2047.

Shahin R, Mansi I, Swellmeen L, Alwidyan T, Al-Hashimi N, Al-Qarar'h Y, Shaheen O. Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors. J Mol Graph Model. 2018;80:327-352.

Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1-4): 27-36.

Chan S, Scheulen ME, Johnston S, Mross K, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005;23(23):5314-22.

Trivedi ND, Armstrong S, Wang H, Hartley M, et al. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. Cancer Med. 2021;10(6):1944-1954.

Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science. 2007;318:977–980.

41, Xia Y, Sun M, Xie Y, Shu R. mTOR Inhibition Rejuvenates the Aging Gingival Fibroblasts Through Alleviating Oxidative Stress. Oxid Med Cell Longev. 2017;6292630.

An JY, Quarles EK, Mekvanich S, Kang A, Liu A, Santos D, et al. . Rapamycin Treatment Attenuates Age-Associated Periodontitis in Mice. GeroScience. 2017;39(4):457–63.

Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory Functions of mTOR Inhibition. Nat Rev Immunol. 2009;9(5): 324–37.